Do I Have Breast Cancer?
More than half of all women will have a lump or nodule in their breast, but most lumps and nodules are not cancer
Disease
Medical
MIT | Use artificial intelligence to improve early breast cancer diagnosis
Every year, 40000 women die of breast cancer in the United States alone. When cancers are discovered at an early stage, they can often be cured. Mammography is the best alternative diagnostic method, but this method also has shortcomings. It often results in false positive results, leading to unnecessary surgery.
Medical
Breast Cancer: a Brighter Future For Patients As New Cutting-Edge Drugs Continue To Emerge!
With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.
Apparatus
New Drug Expected For Patients With Low HER2 Expression, FDA Grants Priority Review Status To Enhertu
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
Medical
Power To The Brain! HER2-Targeted Drugs For Breast Cancer To Look Forward To!
DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.
Apparatus
Heavyweight! First ADC Drug Approved For Hormone Receptor-Positive Breast Cancer!
The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.
Apparatus
The New Generation Of Breast Cancer SERD Drug, Elastoxan, Shows Promise!
A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.
Hospital
Sagara Hospital, Japan
Dedicated to women's medical care and cancer treatment with a focus on breast cancer treatment, Boekiyo has earned a reputation throughout Japan as a specialist breast cancer hospital. Based on the professionalism and quality of care cultivated for women's medical treatment, we promote a full range of treatment for women with a wider range of response capabilities.
Apparatus
Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.
Hospital
St. Marianna University School of Medicine
St. Marianna's Medical University Hospital is one of the top hospitals in Japan, specializing in breast surgery and other related diseases.